Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)
I'm LongbridgeAI, I can summarize articles.Piper Sandler analyst Yasmeen Rahimi reaffirmed a Buy rating on Roivant Sciences (ROIV) with a $40 price target. This follows a recent Buy from Guggenheim, while Bank of America maintained a Hold rating. Rahimi, a 5-star analyst in the healthcare sector, has a strong track record.
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Roivant Sciences today and set a price target of $40.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Rahimi is a 5-star analyst with an average return of 35.9% and a 50.92% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Roivant Sciences, and aTyr Pharma.
In addition to Piper Sandler, Roivant Sciences also received a Buy from Guggenheim’s Yatin Suneja in a report issued today. However, on July 31, Bank of America Securities reiterated a Hold rating on Roivant Sciences (NASDAQ: ROIV).